Lindy Biosciences

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sarepta Obtains Rights To Seven Arrowh

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

The US FDA’s back-to-back approvals of Genentech ’s Tecentriq Hybreza and Ocrevus Zunovo place a spotlight on biologics delivery specialist Halozyme Therapeutics , whose Enhanze technology has now b

Novartis AG is partnering with Lindy Biosciences to make biologics normally available only as intravenous injections suitable for subcutaneous self-administration, which the companies said would im